Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
نویسندگان
چکیده
OBJECTIVE To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.
منابع مشابه
IN SILICO INVESTIGATION OF THE EFFECT OF LYCOPENE ON THE EXPRESSION OF BRCA1 AND BRCA2 INHIBITOR GENES IN PROSTATE CANCER
Background & Aims: Cancer is a genetic disease that results from mutations in genes that control cell activities. Prostate cancer is one of the most common types of cancers in men. Surgery, radiation therapy, hormone therapy, and chemotherapy are used to treat this disease. These treatments have numerous side effects after treatment, including impotence along with the high cost of treatment. In...
متن کاملIdentification of men with a genetic predisposition to prostate cancer: Targeted screening in men at higher genetic risk and controls-The IMPACT study.
12 Background: IMPACT is a multi-national targeted prostate cancer screening study of men with a known germline mutation which is thought to predispose to the disease. The study is recruiting male BRCA1/2 mutation carriers and a control group, who have tested negative for a mutation present in their family, from 52 centres in 17 countries. METHODS Eligible men aged 40-69 years are offered ann...
متن کاملTargeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
BACKGROUND Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries ...
متن کاملEvaluation of the ELAC2 Ser217Leu and Ala541Thr Polymorphisms in the Patients with Prostate Cancer
Introduction: Prostate cancer is the fifth most common cancer in the world and the second leading cause of cancer death among men. The ELAC2 gene (HPC2 locus) on chromosome 17p11 has been identified as hereditary tumor suppressor genes in prostate cancer. Some evidence showed that ELAC2 Ser217Leu and Ala541Thr polymorphisms were associated with prostate cancer risk. The aim of this study was to...
متن کاملجهش های ژنتیکی جدید در ژن های اصلی سرطان پستان (BRCA1/BRCA2) در زنان ایرانی مبتلا به سرطان پستان زودرس
Background: Breast cancer is the most common female malignancy and the main cause of death in mid-aged women. Genetic germ line mutations in BRCAI/BRCA2 in Iranian women with breast or ovarian cancer have not been yet reported. Materials and methods: Clinical data, family history and blood samples were obtained from 83 females aged less than 45 years with primary breast cancer in order to su...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- BJU international
دوره 107 1 شماره
صفحات -
تاریخ انتشار 2011